Blueprint Medicines Q1 2024 GAAP EPS $1.40 Beats $(1.66) Estimate, Sales $96.116M Beat $80.434M Estimate
Author: Benzinga Newsdesk | May 02, 2024 07:01am
Blueprint Medicines (NASDAQ:
BPMC) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $(1.66) by 184.34 percent. The company reported quarterly sales of $96.116 million which beat the analyst consensus estimate of $80.434 million by 19.50 percent. This is a 51.87 percent increase over sales of $63.287 million the same period last year.
Posted In: BPMC